Fact Checked
Fact Checked
This article has been fact checked by a licensed expert before publication to ensure all information provided is correct and safe.
Why is Nevolat a trusted choice for weight loss?
GLP-1 injections are becoming the go-to treatment for weight loss. There are many to choose from, including Nevolat, one of the first generic weight loss injections. The active ingredient in Nevolat, liraglutide, is supported by many years of data that demonstrate its effectiveness and safety.
And as a generic version of Saxenda, it’s often cheaper than similar alternatives. So if you’re looking for an effective, safe, and affordable treatment, Nevolat is a top contender.
Medically reviewed by
Alexandra Cristina Cowell, Writer & Clinical Content Reviewer
- Liraglutide, the active drug in Nevolat, has over 15 years of data proving its safety, effectiveness, and health benefits beyond weight loss.
- It was released in 2025 and is a generic version of Saxenda (meaning it offers the same results at a lower cost).
- Studies show you can lose an average of 8kg within 56 weeks.
- Side effects are generally mild and manageable, with the most common being nausea, constipation, diarrhoea, and vomiting.
What is Nevolat?
Nevolat is a GLP-1 weight loss injection containing the active ingredient liraglutide. It works by reducing your appetite and making you feel full. This helps you to maintain a calorie-controlled diet and lose weight in the long term. It also improves your overall health and reduces your risk of health conditions, such as cardiovascular disease and diabetes.
Nevolat comes as a daily injection that can deliver five different doses. You’ll start on the lowest dose of 0.6mg, working your way up to the maximum dose of 3mg.
How long has Nevolat been around?
Liraglutide, the active ingredient in Nevolat, was approved in 2010 under the brand name Victoza – a treatment for type 2 diabetes. Then in 2014, liraglutide became the first approved GLP-1 agonist for weight loss under the brand name Saxenda.
This was a significant advancement in weight loss treatment, as it was proven to be much more effective than other medications at the time, such as Orlistat. Additionally, it offered many other benefits, including improved cardiovascular health.
In 2025, a generic version of Saxenda called Nevolat was released. This is the first generic GLP-1 treatment for weight loss and is significantly cheaper than Saxenda.
While Nevolat is technically a new medication, its active component (liraglutide) has been in use for over 15 years.
Is Nevolat the oldest GLP-1?
Byetta (exenatide) was the first approved GLP-1 treatment for type 2 diabetes. It was approved in 2009, making it the oldest GLP-1 treatment, but it was discontinued in 2024 due to manufacturing reasons.
This makes liraglutide one of the oldest GLP-1 treatments that’s still available. Liraglutide has been available since 2010, which is a much longer time than Wegovy (semaglutide) and Mounjaro (tirzepatide). If you have concerns about the safety of Nevolat, keep in mind that it has been prescribed to tens of thousands of people over the years. If there were any serious safety issues affecting a large number of people, the medication would have been discontinued.
Is Nevolat easily accessible?
Nevolat is available from many pharmacies, but it’s a prescription-only medicine; this means you’ll need a clinician to prescribe it to you.
To get Nevolat, you’ll need a BMI of at least 30, or 27 with a weight-related health condition, such as diabetes or high blood pressure. Your clinician will also check your medical history to make sure it’s safe and suitable for you.
How safe is Nevolat?
Most studies have found Liraglutide to be well-tolerated and safe. The most commonly reported side effects were gastrointestinal ones, such as nausea, vomiting, diarrhoea, and constipation – many of these incidents were mild and improved after adjusting to the medicine.
On rare occasions, however, liraglutide can cause more serious side effects or allergic reactions.
Seek medical help right away if you get symptoms like breathing problems, face or throat swelling, or a fast heartbeat — these are signs of an allergic reaction.
Likewise, stop taking Nevolat and speak to a doctor right away if you experience severe and persistent pain in your stomach area, as well as nausea and vomiting. These could be signs of pancreatitis (an inflamed pancreas).
Is there lots of data on Nevolat?
There’s a lot of data showing the effectiveness and safety of liraglutide.
In a systematic review, patients using liraglutide lost an average of 5.24kg of body weight over the treatment course. In another study, 2487 patients taking 3mg of liraglutide lost an average of 8.4kg by week 56, while participants on a placebo only lost 2.8 kg. These findings show that liraglutide is effective for weight loss.
Regarding safety, although many patients reported experiencing side effects, over 90% of these were reported as mild or moderate. The most common side effects included gastrointestinal issues such as nausea, diarrhoea, constipation, and vomiting. These side effects caused 9.9% of patients to withdraw from the trial.
Many studies have been conducted on liraglutide over the years, which have provided a solid understanding of its long-term efficacy and side effects. Additionally, it has passed strict safety regulations in the UK, so if there were any significant issues, it would have been discontinued.
Can Nevolat be considered the safest GLP-1 injection?
Under some conditions, Nevolat can be considered one of the safest GLP-1 treatments. In a study comparing the safety of liraglutide and semaglutide, the results showed that semaglutide 2.4mg had the highest incidence of adverse events, followed by liraglutide 3mg. This suggests that the highest dose of liraglutide is safer than the highest dose of semaglutide. Additionally, many liraglutide side effects were reported as mild and tolerable.
But in another study, liraglutide has the highest rates of adverse events compared to semaglutide and tirzepatide. While this may seem contradictory to the former study, you have to understand that different people react differently to the same medicine. While some people may not experience many side effects with liraglutide, others might find it challenging to manage.
Is Nevolat the best GLP-1 for me?
Nevolat is one of the oldest GLP-1 treatments available for weight loss, and its safety and efficacy have been proven many times in numerous long-term studies.
Compared to other treatments in the market, it’s one of the more affordable options. But there may be a slightly higher risk of experiencing side effects while on it, although they are often mild and tolerable.
If you’re unsure about which weight loss medication is right for you, talk to one of our clinicians who can help you decide which is most suitable for you.
How we source info.
When we present you with stats, data, opinion or a consensus, we’ll tell you where this came from. And we’ll only present data as clinically reliable if it’s come from a reputable source, such as a state or government-funded health body, a peer-reviewed medical journal, or a recognised analytics or data body. Read more in our editorial policy.
Reference Popover #ref1
Treated trusted source
Astrup, A., et al. (2011).
Safety, tolerability, and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. International Journal of Obesity (2005), 36(6), 843.
Reference Popover #ref2
Treated trusted source
Klein, D. J., et al. (2014).
Liraglutide's Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Pediatric Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Technology & Therapeutics, 16(10), 679.
Reference Popover #ref3
Treated trusted source
Xie, Z., et al. (2022).
Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review. Clinical Epidemiology, 14, 1463.
Reference Popover #ref4
Treated trusted source
Pi-Sunyer, X., et al. (2015).
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, [online] 373(1), pp.11–22.
Reference Popover #ref5
Treated trusted source
Xie, Z., et al. (2025).
Comparative Safety of GLP-1/GIP Co-Agonists Versus GLP-1 Receptor Agonists for Weight Loss in Patients with Obesity or Overweight: A Systematic Review. Diabetes, Metabolic Syndrome and Obesity, 18, 2837.
Reference Popover #ref6
Treated trusted source
Vemulapalli, H. S., et al. (2023).
Safety and Efficacy of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials. Cureus, 15(9), e45421.
Reference Popover #ref7
Treated trusted source
Vemulapalli, H.S., et al. (2023).
Safety and Efficacy of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials. Cureus, 15(9).
Tell us what you want to hear.
Have a subject you’d like us to cover in a future article? Let us know.
Give us the inbox treatment.
We're making healthcare more about you. Sign up to our newsletter for personalised health articles that make a difference.
Disclaimer: The information provided on this page is not a substitute for professional medical advice, diagnosis, or treatment. If you have any questions or concerns about your health, please talk to a doctor.
Find treatment
I'm looking for
Popular searches:
Sign up to our newsletter for all the latest on Weight loss and more.
By clicking 'Subscribe now' you're agreeing to our Privacy Policy.